Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61


Follicle-stimulating hormone receptor as a target in the redirected T-cell therapy for cancer.

Urbanska K, Stashwick C, Poussin M, Powell DJ Jr.

Cancer Immunol Res. 2015 Jun 25. pii: canimm.0047.2015. [Epub ahead of print]


A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.

Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ Jr.

Oncotarget. 2015 Jun 19. [Epub ahead of print]


Advances and prospects in adoptive cell transfer therapy for ovarian cancer.

Urbanska K, Powell DJ Jr.

Immunotherapy. 2015;7(5):473-6. doi: 10.2217/imt.15.21. No abstract available.


Tumor infiltrating lymphocytes in ovarian cancer.

Santoiemma PP, Powell DJ Jr.

Cancer Biol Ther. 2015;16(6):807-20. doi: 10.1080/15384047.2015.1040960. Epub 2015 Apr 20.


Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.

Lynn RC, Poussin M, Kalota A, Feng Y, Low PS, Dimitrov DS, Powell DJ Jr.

Blood. 2015 May 28;125(22):3466-76. doi: 10.1182/blood-2014-11-612721. Epub 2015 Apr 17.


CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.

Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ Jr, Czerniecki BJ.

Cancer Immunol Res. 2015 May;3(5):455-63. doi: 10.1158/2326-6066.CIR-14-0208. Epub 2015 Mar 19.


The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.


Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.

Urbanska K, Lynn RC, Stashwick C, Thakur A, Lum LG, Powell DJ Jr.

J Transl Med. 2014 Dec 13;12:347. doi: 10.1186/s12967-014-0347-2.


T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.

Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, Powell DJ Jr, Coukos G.

Cancer Immunol Res. 2015 Jan;3(1):68-84. doi: 10.1158/2326-6066.CIR-14-0192. Epub 2014 Oct 30.


A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr.

Hum Gene Ther. 2014 Aug;25(8):730-9. doi: 10.1089/hum.2014.006.


B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.

Smith JB, Stashwick C, Powell DJ Jr.

Gynecol Oncol. 2014 Jul;134(1):181-9. doi: 10.1016/j.ygyno.2014.03.553. Epub 2014 Mar 20. Review.


Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr.

Cancer Immunol Res. 2013 Jul;1(1):43-53.


Therapeutic dendritic cell-based cancer vaccines: the state of the art.

Strioga MM, Felzmann T, Powell DJ Jr, Ostapenko V, Dobrovolskiene NT, Matuskova M, Michalek J, Schijns VE.

Crit Rev Immunol. 2013;33(6):489-547. Review.


CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ Jr.

Clin Cancer Res. 2014 Jan 1;20(1):44-55. doi: 10.1158/1078-0432.CCR-13-0945. Epub 2013 Sep 17.


A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.


Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.

Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ Jr, Scholler N.

Cancer Res. 2013 Aug 1;73(15):4820-9. doi: 10.1158/0008-5472.CAN-12-3457. Epub 2013 May 30.


Remarkable stability of clinical grade reagents for gene-engineered T-lymphocyte production.

Johnson LA, Powell DJ Jr.

Cytotherapy. 2013 May;15(5):523-4. doi: 10.1016/j.jcyt.2013.02.012. No abstract available.


Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G.

Oncoimmunology. 2013 Jan 1;2(1):e22664.


IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.

Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, Powell DJ Jr, June CH, de Gruijl TD.

J Transl Med. 2013 Feb 12;11:37. doi: 10.1186/1479-5876-11-37.


Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.

Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ Jr.

Hum Gene Ther. 2013 Mar;24(3):295-305. doi: 10.1089/hum.2012.143. Epub 2013 Mar 1.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk